University Clinical Hospital Virgen De La Arrixaca

The University Clinical Hospital Virgen De La Arrixaca is running a strong program in hematologic malignancies and related blood disorders, with studies focused on follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, multiple myeloma, and myelofibrosis. These trials are mainly designed to test new treatment strategies, improve disease control, and extend remission for patients with relapsed, refractory, or newly diagnosed disease.

• Evaluating new approaches for follicular lymphoma and marginal zone lymphoma
• Testing therapies for diffuse large B-cell lymphoma and other aggressive blood cancers
• Studying treatment options in multiple myeloma and myelofibrosis

Research at this site also includes cell therapy and other advanced oncology approaches aimed at improving outcomes when standard treatments are no longer enough.

Clinical research in breast cancer and ovarian cancer is a major focus in Murcia, covering early-stage, advanced, and recurrent disease. The studies explore better ways to prevent recurrence, strengthen endocrine treatment, and improve results for patients undergoing surgery and systemic therapy.

• Investigating therapies for early breast cancer, metastatic breast cancer, and triple-negative breast cancer
• Studying treatment strategies for advanced ovarian cancer and related gynecologic cancers
• Assessing new options to reduce recurrence and improve long-term disease control

Several trials also examine how to better match treatment to tumor biology, especially in hormone receptor-positive and HER2-negative disease.

The site has an extensive portfolio in cardiovascular diseases and stroke prevention, including studies in atrial fibrillation, heart failure, coronary artery disease, and atherosclerotic cardiovascular disease. These trials are generally focused on preventing major events, improving heart function, and finding safer long-term treatment options.

• Testing therapies to lower the risk of stroke and systemic embolism
• Evaluating treatments for heart failure, hypertrophic cardiomyopathy, and dilated cardiomyopathy
• Studying prevention of major adverse cardiovascular events in high-risk patients

At University Clinical Hospital Virgen De La Arrixaca, this work reflects a broad effort to improve both early prevention and long-term cardiovascular care.

Research in neurological and immune-mediated diseases includes studies in multiple sclerosis, acute ischemic stroke, amyotrophic lateral sclerosis, and graft-versus-host disease. The aim is to better control inflammation, protect nervous system function, and support recovery in difficult-to-treat conditions.

• Exploring new options for relapsing and progressive multiple sclerosis
• Assessing treatments for acute stroke and recovery after brain injury
• Studying therapies for steroid-refractory acute graft-versus-host disease and amyotrophic lateral sclerosis

These trials combine neurology and immunology research to address conditions with major unmet medical needs.

The trial portfolio also includes respiratory diseases, viral infections, and metabolic disorders, such as fibrotic lung disease, HIV-1, and hypertriglyceridemia. These studies are aimed at improving long-term safety, disease control, and prevention of complications.

• Evaluating treatments for fibrotic lung disease and chronic lung inflammation
• Studying long-term management in HIV-1
• Assessing therapies for hypertriglyceridemia and related cardiovascular risk

This mix of research shows the hospital’s broad interest in chronic disease management across several therapeutic areas.

Additional studies at the site address female urogenital health, pregnancy complications, and inherited blood disorders. Current research includes preeclampsia prevention and treatment approaches for hemophilia, with a focus on safer care for women and patients with bleeding conditions.

• Preventing preterm preeclampsia and related pregnancy complications
• Evaluating supportive care for hemophilia A and hemophilia B
• Improving treatment safety in patients with inherited bleeding disorders

These studies broaden the research profile of University Clinical Hospital Virgen De La Arrixaca beyond oncology and cardiovascular care.